Pulmonary Embolism and Increased Levels of D-Dimer in Patients with Coronavirus DiseaseLetters to the Editor Published on 2020-10-012022-10-31 Journal: Emerging Infectious Diseases [Category] Coronavirus, MERS, [키워드] coronavirus disease COVID-19 Cytokine storm Embolism Factor XIII deficiency Increased interleukin-6 receptor Level plasminogen activator proteolytic enzymes pulmonary respiratory infections SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 Tocilizumab transient hypercoagulable state Venous Thromboembolism viruses [DOI] 10.3201/eid2610.202127 PMC 바로가기 [Article Type] Letters to the Editor
Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19)Article Published on 2020-10-012023-07-11 Journal: Microbes and infection [Category] SARS, [키워드] acute respiratory distress syndrome Biomarkers COVID-19 Predictive Factors SARS-CoV-2 Tocilizumab [DOI] 10.1016/j.micinf.2020.06.005 PMC 바로가기
Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumabResearch article Published on 2020-10-012022-10-05 Journal: International Journal of Infectious Diseases [Category] Coronavirus, SARS, 치료법, [키워드] 95% confidence interval addition Anakinra anti-cytokine anti-cytokine treatment anti-inflammatory treatment Clinical severity conducted Controlled trial Corticosteroid Corticosteroids COVID-19 COVID-19 cytokine storm criteria Cytokine storm dead died disease severity Electronic health records had more hazard Intubated intubation Laboratory median objective outcome Patient patients died patients treated randomization Respiratory failure Result retrospective cohort study Sepsis Seven specific type statistically significant to define Tocilizumab treated Treatment treatment initiation treatment with anakinra variable [DOI] 10.1016/j.ijid.2020.07.081 [Article Type] Research article
Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab토실리주맙을 투여받는 COVID-19 환자의 급성 고중성지방혈증Comment Published on 2020-10-012022-09-12 Journal: Journal of medical virology [Category] MERS, SARS, 진단, [키워드] Abstract coronavirus disease disease control immune immune responses immunodulators interleukin patients with COVID-19 receiving Tocilizumab virus virus classification [DOI] 10.1002/jmv.25907 PMC 바로가기 [Article Type] Comment
IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational studyClinical Trial Published on 2020-09-302023-07-01 Journal: The Journal of Allergy and Clinical Immunology [Category] SARS, [키워드] ARDS, acute respiratory distress syndrome CAR, Chimeric antigen receptor COPD, Chronic obstructive pulmonary disease COVID-19 COVID-19, Coronavirus disease 2019 CRP, C-reactive protein FiO2, fraction of inspired oxygen IL-6 IL-6R, IL-6 receptor IMV, invasive mechanical ventilation Invasive mechanical ventilation IQR, interquartile range LDH, lactate dehydrogenase PaO2, Arterial oxygen tension ROC, Receiver-operating characteristic SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 TCZ, tocilizumab Tocilizumab [DOI] 10.1016/j.jaci.2020.09.018 PMC 바로가기 [Article Type] Clinical Trial
Predictors of Severity in Covid-19 Patients in Casablanca, MoroccoInfectious Disease Published on 2020-09-292022-10-31 Journal: Cureus [Category] COVID-19, [키워드] 95% confidence interval Acute kidney injury acute respiratory distress acute respiratory syndrome affected ARDS C-reactive protein chest scan Cluster Clusters Comorbidities Comorbidity Coronary heart disease coronavirus coronavirus disease COVID-19 COVID-19 patient COVID-19 severity Critical case CRP D-dimer described diabete died disease severity dry cough Dyspnea eight epidemiological Factor ferritin Fever form Genetic studies hospital Hospital admission Hydroxychloroquine hypertension ICU ICU patient ICU Patients illness onset infected patient Infection intensive care interquartile range IQR laboratory data lactate dehydrogenase logistic regression model lymphopenia male median age median time men Mild moderate Morocco multivariable logistic regression non-severe patient North Odds ratio Older Older age outcome oxygen saturation pandemic Patient patients patients with comorbidities predict Predictive Predictive Factors reported Reporting required Result retrospective risk factor SARS-CoV-2 SARS-COV-2 infection separated Seven severe COVID-19 Severe patient severity single-center structures syndrome System Thromboembolic event Tocilizumab transferred univariable univariable analysis university were infected [DOI] 10.7759/cureus.10716 PMC 바로가기 [Article Type] Infectious Disease
Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilationResearch Published on 2020-09-292022-11-01 Journal: Critical Care [Category] COVID-19, SARS, [키워드] 95%CI acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome adjusted Admission age ARDS ARF association asymptomatic patient case-control study Comorbidity consecutive patient Controlled trial coronavirus coronavirus disease COVID-19 COVID-19 patient CRP develop died effective effective therapy Efficacy and safety elevated Evidence Follow-up IL-6 levels in-hospital mortality rate Infection intravenous Intubated Kaplan-Meier method lung lesion mechanical ventilation Multivariate analysis NIV noninvasive Noninvasive ventilation outcome overall mortality Patient patients patients with COVID-19 Primary outcome Probability progression Pulmonology receiving reduced risk required Respiratory failure respiratory impairment Result retrospective SARS-CoV-2 severe COVID-19 Severe COVID-19 pneumonia severity significantly lower syndrome TCZ the patient Tocilizumab total patient treated Treatment Two patient unit worsening [DOI] 10.1186/s13054-020-03306-6 PMC 바로가기 [Article Type] Research
Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 ImmunopathologyImmunology Published on 2020-09-232022-11-01 Journal: Frontiers in Immunology [Category] COVID-19, MERS, SARS, [키워드] Activation Admission analyzed association control group correlation corticoid COVID-19 COVID-19 patients disease ELISA Evidence healthy control Hospital admission hospitalized patients Hydroxychloroquine ICU ICU admission immunopathology Increased indicate Infection Inflammatory marker inflammatory markers investigated knowledge Laboratory parameters Level marker moderate monocyte Monocyte activation monocyte-macrophage non-ICU non-ICU patient positive positive correlation recruited Result role sCD14 sCD163 severity significantly higher Tocilizumab [DOI] 10.3389/fimmu.2020.560381 PMC 바로가기 [Article Type] Immunology
COVID-19 and the newly rediscovered multidisciplinarityForeword Published on 2020-09-222022-10-31 Journal: Immunotherapy [Category] Coronavirus, MERS, SARS, [키워드] anti-PD-1/PD-L1 COVID-19 Immunosuppressed Immunotherapy Janus kinase inhibitors pandemic SARS-CoV-2 Tocilizumab virus [DOI] 10.2217/imt-2020-0205 PMC 바로가기 [Article Type] Foreword
Anti-Rheumatic Drugs for the Fight Against the Novel Coronavirus Infection (SARSCoV-2): What is the Evidence?Review Published on 2020-09-212022-10-31 Journal: Mediterranean Journal of Rheumatology [Category] COVID-19, [키워드] “cytokine storm” ACE2 receptor addition Against anti-cytokine antimalarial Asymptomatic cause clinical trial Colchicine Course COVID-19 COVID-19 infection COVID-19 symptoms current cytokine Cytokine storm Cytokines death develop drug dysregulated elderly expressed high risk Hydroxychloroquine IL-1 IL-6 immune system immunoglobulins intensive care intravenous male medical condition novel occur Other Patient patients plethora positive-sense single-stranded RNA pro-inflammatory cytokine producing Protein pulse reduce respiratory cells SARS-CoV-2 selected severe complications severely infected patient shown smoker spike Spike protein therapy Tocilizumab Treatment ventilatory support virus [DOI] 10.31138/mjr.31.3.259 PMC 바로가기 [Article Type] Review